PathoGene Reels in $750K in Seed Funds to Develop PCR-Based Infectious Disease Dxs
August 19, 2010
PathoGene Reels in $750K in Seed Funds to Develop PCR-Based Infectious Disease Dxs
The company is developing and validating assays for difficult-to-treat and drug-resistant infectious diseases based primarily on targets, biomarkers, and PCR primers developed at the Translational Genomics Research Institute and Northern Arizona University.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- DxNA Licenses Staph Assay from PathoGene for Use on GeneStat System
May 9, 2013 / PCR Insider - Life Tech Buys QC Firm AcroMetrix
January 12, 2010 / GenomeWeb Daily News - People in the News
April 14, 2009 / BioArray News - Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider - Cynvenio to Offer Clinical PCR Testing of Isolated Circulating Tumor Cells for Select Targets
April 11, 2013 / PCR Insider